Tenax receives NOA from USPTO for patent for levosimendan in PH-HFpEF

Tenax Therapeutics announced that it has received a Notice of Allowance from the United States Patent and Trademark Office USPTO for its patent application with claims covering the use of IV levosimendan in the treatment of pulmonary hypertension with heart failure with preserved ejection fraction or PH-HFpEF. The patent is expected to last until 2040 and will provide the Company with substantial added intellectual property IP protection for the use of levosimendan in the treatment of PH-HFpEF patients in the United States. This Notice of Allowance further builds upon the Company's significant IP for levosimendan, which includes U.S. Patent No. 11,213,524 that was issued in January 2022 and covers all medical uses in humans of the subcutaneous formulation of levosimendan.Chris Giordano, Tenax Therapeutics' Chief Executive Officer, stated, "This notice of allowance represents an important milestone in the Company's development of broad IP protection for the use of levosimendan to treat the estimated 1.5 million-plus patients in the United States who suffer from PH-HFpEF and who currently have no FDA approved therapies to treat their condition. The protections this patent will provide are based on key discoveries from the HELP Study - the first study to demonstrate improved exercise tolerance in patients with this deadly disease. USPTO's acknowledgement of the novelty of this targeted use of levosimendan increases our confidence that our pending patent applications, which are based on further data from the HELP patients who transitioned from IV to oral levosimendan, will also be afforded IP protection."